Denosumab with trade name Prolia, is an FDA-approved drug for the treatment of patients with osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Denosumab is a fully human monoclonal antibody that works as a RANK ligand (RANKL) inhibitor. Denosumab can bind RANKL, preventing RANKL from activating RANK, its receptor on the osteoclast surface.
Anti-Denosumab Antibody (2H7), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Denosumab.
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.005-0.1 µg/ml
Synonyms Mouse monoclonal to Denosumab/Prolia
Description Denosumab with trade name Prolia, is an FDA-approved drug for the treatment of patients with osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Denosumab is a fully human monoclonal antibody that works as a RANK ligand (RANKL) inhibitor. Denosumab can bind RANKL, preventing RANKL from activating RANK, its receptor on the osteoclast surface. Anti-Denosumab Antibody (2H7), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Denosumab.
Host Species Mouse
Conjugation Unconjugated
Immunogen Denosumab Purification Protein A affinity column
Clone 2H7
Properties
- Subclass IgG1,K Concentration 0.5 mg/ml, lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
- Reconstitution Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
- Specificity The product is specific for Denosumab.
- Storage The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
- Note GenScript can customize this product per customer's request including product size, buffer components, etc.
Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.005-0.1 µg/ml
Other applications: user-optimized